Company intelligence / Profile preview
United Biomedical, Inc.
New York, USAunitedbiomedical.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
United Biomedical, Inc. (UBI) develops immunotherapeutics and vaccines for chronic and infectious diseases using proprietary synthetic peptide-based technologies and monoclonal antibodies. Its spinoffs have advanced candidates such as UB421 for HIV into multinational Phase II/III trials. The company has enabled the sale of billions of units based on its technologies in both human and animal health but does not market its own branded products directly.[1][2][3]
- Therapeutic areas
- OtherImmunologyNeurologyInfectious Diseases
- Modalities
- Synthetic peptidesMonoclonal antibodies (mAbs)Protein drugs
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Collaborates with global firms for commercializationpartnered with Taiwan government to form UBI Asia
Beyond the preview
Go deeper on United Biomedical, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on United Biomedical, Inc..